Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau phosphorylated at threonine 231 (p-tau231) is one such biomarker in CSF but its usefulness as a blood biomarker is currently unknown. Here, we developed an ultrasensitive Single molecule array (Simoa) for the quantification of plasma p-tau231 which was validated in four independent cohorts ( n = 588) in different settings, including the full AD continuum and non-AD neurodegenerative disorders. Plasma p-tau231 was able to identify patients with AD and differentiate them from amyloid-β negative cognitively unimpaired (CU) older adults with high accuracy (AUC = 0.92–0.94). Plasma p-tau231 also distinguished AD patients from patients with non-AD neurodegenerative disorders (AUC = 0.93), as well as from amyloid-β negative MCI patients (AUC = 0.89). In a neuropathology cohort, plasma p-tau231 in samples taken on avergae 4.2 years prior to post-mortem very accurately identified AD neuropathology in comparison to non-AD neurodegenerative disorders (AUC = 0.99), this is despite all patients being given an AD dementia diagnosis during life. Plasma p-tau231 was highly correlated with CSF p-tau231, tau pathology as assessed by [ 18 F]MK-6240 positron emission tomography (PET), and brain amyloidosis by [ 18 F]AZD469 PET. Remarkably, the inflection point of plasma p-tau231, increasing as a function of continuous [ 18 F]AZD469 amyloid-β PET standardized uptake value ratio, was shown to be earlier than standard thresholds of amyloid-β PET positivity and the increase of plasma p-tau181. Furthermore, plasma p-tau231 was significantly increased in amyloid-β PET quartiles 2–4, whereas CSF p-tau217 and plasma p-tau181 increased only at quartiles 3–4 and 4, respectively. Finally, plasma p-tau231 differentiated individuals across the entire Braak stage spectrum, including Braak staging from Braak 0 through Braak I–II, which was not observed for plasma p-tau181. To conclude, this novel plasma p-tau231 assay identifies the clinical stages of AD and neuropathology equally well as plasma p-tau181, but increases earlier, already with subtle amyloid-β deposition, prior to the threshold for amyloid-β PET positivity has been attained, and also in response to early brain tau deposition. Thus, plasma p-tau231 is a promising novel biomarker of emerging AD pathology with the potential to facilitate clinical trials to identify vulnerable populations below PET threshold of amyloid-β positivity or apparent entorhinal tau deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Plasma p-tau231 concentration correlates with PET and CSF tau and Aβ. The brain maps show the results of linear regressions false discovery rate corrected for multiple comparisons at P < 0.05, whereas the plots show the results of Spearman rank correlation between biomarkers. a Plasma p-tau231 concentrations were associated with [18F]MK-6240 SUVR across the cortex with the highest association in the temporal and posterior cingulate cortices as well as with b CSF p-tau231 concentrations. c Plasma p-tau231 correlates with [18F]AZD4694 SUVR across the cortex and with d CSF Aβ1-42 concentrations](https://figures.cochat.ai/paper-figures/11450d600b6547cd8ddd582223ba6f57/plasma-p-tau231-a-new-biomarker-for-incipient-alzheimers-disease-pathology-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Among proposed blood tau biomarkers,18,19,20,21 phosphorylated tau at threonine 217 (p-tau217) has consistently shown high performance in differentiating AD from other neurodegenerative disorders10,22 and in detecting AD pathology in patients with mild cognitive impairment (MCI).22”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“The new plasma p-tau231 Simoa assay has been previously described and validated2.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Plasma measures of phosphorylated tau at Thr181 (p-tau181), Thr217 (p-tau217) and Thr231 (p-tau231) have high diagnostic accuracy in differentiating AD from other neurodegenerative disorders in clinical studies1–3, which are validated by postmortem neuropathological studies1,2,4.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Subsequently, the first blood analysis of p-tau231 (ref. 2) demonstrated earlier increases than plasma p-tau181 in a small set of participants.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“P-tau231 levels in blood have also recently been demonstrated to increase earlier than p-tau18160 (Tissot et al., 2022), however, a direct comparison with p-tau217 in early preclinical disease is not currently available.”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [60]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
Cited by
Items 201–300 of 769
Snellman, A., Ekblad, L. L., Ashton, N. J., Karikari, T. K., Lantero‐Rodriguez, J., Pietilä, E. A., Koivumäki, M., Helin, S., Karrasch, M., Zetterberg, H., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106175 · Cited by 36
Self-citationSanchez-Rodriguez, L. M., Bezgin, G., Carbonell, F., Therriault, J., Arias, J. F., Servaes, S., Rahmouni, N., Tissot, C., Stevenson, J., Karikari, T. K., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06217-2 · Cited by 36
Self-citationWojdała, A. L., Bellomo, G., Gaetani, L., Teunissen, C. E., Parnetti, L., & Chiasserini, D. (2025) · Nature Communications · doi:10.1038/s41467-024-54878-8 · Cited by 34
Gu, Y., Honig, L. S., Kang, M. S., Bahl, A., Sanchez, D. L., Reyes‐Dumeyer, D., Manly, J. J., Dage, J. L., Lantigua, R., Brickman, A. M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13652 · Cited by 34
P-tau217 in Alzheimer’s disease
Telser, J., Risch, L., Saely, C. H., Grossmann, K., & Werner, P. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.03.018 · Cited by 33
González‐Escalante, A., Milà‐Alomà, M., Brum, W. S., Ashton, N. J., Ortiz-Romero, P. L., Shekari, M., del Campo, M., Anastasi, F., Quijano‐Rubio, C., Kollmorgen, G., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105741 · Cited by 33
Self-citationPhospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
Meyer, S. D., Vanbrabant, J., Schaeverbeke, J. M., Reinartz, M., Luckett, E. S., Dupont, P. J., Laere, K. V., Stoops, E., Vanmechelen, E., Poesen, K., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51553 · Cited by 33
Self-citationBrown, J., Camporesi, E., Lantero‐Rodriguez, J., Olsson, M., Wang, A., Medem, B., Zetterberg, H., Blennow, K., Karikari, T. K., Wall, M. J., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01562-5 · Cited by 34
Self-citationHead-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
Lu, J., Ma, X., Zhang, H., Xiao, Z., Li, M., Wu, J., Ju, Z., Chen, L., Zheng, L., Ge, J., et al. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00365-x · Cited by 33
Novel Biomarkers for Alzheimer’s Disease: Plasma Neurofilament Light and Cerebrospinal Fluid
Abukuri, D. N. (2024) · International Journal of Alzheimer s Disease · doi:10.1155/2024/6668159 · Cited by 32
Predictive blood biomarkers and brain changes associated with age-related cognitive decline
Saunders, T. S., Pozzolo, F. E., Heslegrave, A., King, D., McGeachan, R. I., Spires-Jones, M. P., Harris, S. E., Ritchie, C. W., Terrera, G. M., Deary, I. J., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad113 · Cited by 32
Self-citationLantero‐Rodriguez, J., Tissot, C., Snellman, A., Servaes, S., Benedet, A. L., Rahmouni, N., Montoliu‐Gaya, L., Therriault, J., Brum, W. S., Stevenson, J., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13119 · Cited by 32
Self-citationA critical appraisal of blood-based biomarkers for Alzheimer’s disease
Lista, S., Mapstone, M. E., Caraci, F., Emanuele, E., López‐Ortiz, S., Martín-Hernández, J., Triaca, V., Imbimbo, C., Gabelle, A., Mielke, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102290 · Cited by 32
The blood biomarkers puzzle – A review of protein biomarkers in neurodegenerative diseases
Barro, C., & Zetterberg, H. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109281 · Cited by 32
Self-citationMaschio, V. P. D., Roveta, F., Bonino, L., Boschi, S., Rainero, I., & Rubino, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178564 · Cited by 31
Yuan, J., Pedrini, S., Thota, R. N., Doecke, J. D., Chatterjee, P., Sohrabi, H. R., Teunissen, C. E., Verberk, I. M. W., Stoops, E., Vanderstichele, H., et al. (2023) · npj Aging · doi:10.1038/s41514-023-00114-4 · Cited by 31
Self-citationPilotto, A., Parigi, M., Bonzi, G., Battaglio, B., Ferrari, E., Mensi, L., Benussi, A., Caratozzolo, S., Cosseddu, M., Turrone, R., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215646 · Cited by 30
Self-citationInduction of Brain Insulin Resistance and Alzheimer’s Molecular Changes by Western Diet
Mietelska‐Porowska, A., Domańska, J. M., Want, A., Więckowska‐Gacek, A., Chutorański, D., Koperski, M., & Wojda, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094744 · Cited by 30
Mohammadi, Z., Alizadeh, H., Marton, J., & Cumming, P. D. (2023) · Biomolecules · doi:10.3390/biom13020290 · Cited by 30
Li, Z., Fan, Z., & Zhang, Q. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230799 · Cited by 30
Krawczuk, D., Kulczyńska‐Przybik, A., & Mroczko, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158132 · Cited by 30
Differential roles of Alzheimer's disease plasma biomarkers in stepwise biomarker‐guided diagnostics
Jang, H., Shin, D., Yoo, H., Zetterberg, H., Blennow, K., González‐Ortiz, F., Ashton, N. J., Day, T. A., Lee, E. H., Yun, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14526 · Cited by 29
Self-citationSolje, E., Benussi, A., Buratti, E., Remes, A. M., Haapasalo, A., & Borroni, B. (2021) · Diagnostics · doi:10.3390/diagnostics11050788 · Cited by 30
Tu, L. M. T. P. P. L. M., & Cho, S. (2022) · Biomedicines · doi:10.3390/biomedicines10010093 · Cited by 29
Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology
Sunde, A. L., Alsnes, I. V., Aarsland, D., Ashton, N. J., Tovar, D., Santis, G. D., Blennow, K., Zetterberg, H., & Kjosavik, S. R. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12439 · Cited by 29
Self-citationPlasma Alzheimer's disease biomarker variability: Amyloid‐independent and amyloid‐dependent factors
Lee, E. H., Kang, S. H., Shin, D., Kim, Y. J., Zetterberg, H., Blennow, K., González‐Ortiz, F., Ashton, N. J., Cheon, B. K., Yoo, H., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14368 · Cited by 28
Self-citationTau proteins in blood as biomarkers of Alzheimer’s disease and other proteinopathies
Verde, F. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02471-y · Cited by 28
Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
Klafki, H., Morgado, B., Wirths, O., Jahn, O., Bauer, C., Esselmann, H., Schuchhardt, J., & Wiltfang, J. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00390-4 · Cited by 28
Ferreira, P. C. L., Ferrari‐Souza, J. P., Tissot, C., Bellaver, B., Leffa, D. T., Lussier, F. Z., Povala, G., Therriault, J., Benedet, A. L., Ashton, N. J., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207115 · Cited by 28
Self-citationKorologou‐Linden, R., Kalsi, J., Kafetsouli, D., Olawale, A., Wingfield, D., Mummery, D., Hayhoe, B. W. J., Robinson, O., Majeed, A., & Middleton, L. T. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.83 · Cited by 28
Mendes, A. J., Ribaldi, F., Lathuilière, A., Ashton, N. J., Zetterberg, H., Abramowicz, M., Scheffler, M., Assal, F., Garibotto, V., Blennow, K., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01478-9 · Cited by 28
Self-citationValidating blood tests as a possible routine diagnostic assay of Alzheimer’s disease
Kodosaki, E., Zetterberg, H., & Heslegrave, A. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2289553 · Cited by 27
Self-citationJash, S., Banerjee, S., Cheng, S., Wang, B., Qiu, C., Kondo, A., Ernerudh, J., Zhou, X. Z., Lu, K. P., & Sharma, S. (2023) · Nature Communications · doi:10.1038/s41467-023-41144-6 · Cited by 27
Cáceres, C., Heusser, B., Garnham, A., & Moczko, E. (2023) · Cells · doi:10.3390/cells12232669 · Cited by 27
Short-term variability of Alzheimer’s disease plasma biomarkers in a mixed memory clinic cohort
Clemmensen, F. K., Gramkow, M. H., Simonsen, A. H., Ashton, N. J., Huber, H., Blennow, K., Zetterberg, H., Waldemar, G., Hasselbalch, S. G., & Frederiksen, K. S. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01658-7 · Cited by 27
Self-citationPhosphorylation-Induced Self-Coacervation versus RNA-Assisted Complex Coacervation of Tau Proteins
Allahyartorkaman, M., Chan, T.-H., Chen, E. H.-L., Ng, S.-T., Chen, Y., Wen, J., Ho, M., Yen, H., Kuan, Y., Kuo, M., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14728 · Cited by 26
The PREVENT‐AD cohort: Accelerating Alzheimer's disease research and treatment in Canada and beyond
Villeneuve, S., Poirier, J., Breitner, J. C. S., Tremblay‐Mercier, J., Remz, J., Raoult, J., Yakoub, Y., Gallego-Rudolf, J., Qiu, T., Valdez, A. F., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70653 · Cited by 26
Self-citationFluid biomarkers for neurodegenerative diseases: a comprehensive update
Valletta, M., Briel, N., Yuksekel, I., Barboure, M. C., Coward, A. R., Houwer, J. F. H. D., Fawad, A., González-Mayoral, A., Iaccarino, G., Martínez‐Dubarbie, F., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01919-z · Cited by 26
Self-citationÁlvarez‐Sánchez, L., Peña‐Bautista, C., Baquero, M., & Cháfer‐Pericás, C. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215093 · Cited by 26
Wang, Y.-T., Therriault, J., Tissot, C., Servaes, S., Rahmouni, N., Macedo, A. C., Arias, J. F., Mathotaarachchi, S. S., Stevenson, J., Lussier, F. Z., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01509-5 · Cited by 26
Self-citationWang, J., Lu, X., & He, Y. (2025) · Biosensors · doi:10.3390/bios15020085 · Cited by 26
Giampietri, L., Belli, E., Beatino, M. F., Giannoni, S., Palermo, G., Campese, N., Tognoni, G., Siciliano, G., Ceravolo, R., Luca, C. D., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12040796 · Cited by 25
Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation
Wu, L., Gilyazova, N., Ervin, J. F., Wang, S. J., & Xu, B. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00342 · Cited by 25
Blood biomarkers and neurodegeneration in individuals exposed to repetitive head impacts
Bernick, C. B., Shan, G., Ritter, A. R., Ashton, N. J., Blennow, K., Lantero‐Rodriguez, J., Snellman, A., & Zetterberg, H. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01310-w · Cited by 25
Self-citationKong, Q., Liu, C., Zhang, Y., He, Y., Zhang, R., Wang, Y., Zhou, Q., & Cui, F. (2024) · Microchimica Acta · doi:10.1007/s00604-024-06395-0 · Cited by 25
Eastwood, S., Meyer, M. R., Kirmess, K. M., Wente‐Roth, T. L., Irvin, F., Holubasch, M. S., Verghese, P. B., West, T., Braunstein, J. B., Yarasheski, K. E., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14161739 · Cited by 24
Mitolo, M., Lombardi, G., Manca, R., Nacmias, B., & Venneri, A. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12674-w · Cited by 24
Digital Immunoassay for Proteins: Theory, Methodology, and Clinical Applications
Liu, X., Zhang, Q., Zong, C., & Gai, H. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c05421 · Cited by 24
Lucena, P. B., Vanherle, S., Lodder, C., de Ravé, M. G., Stancu, I., Lambrichts, I., Vangheluwe, R., Bruffaerts, R., & Dewachter, I. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02458-9 · Cited by 24
Hansen, É. D. O., Dias, N. S., Burgos, I. C. B., Costa, M. V., Teixeira‐Carvalho, A., Teixeira, A. L., Barbosa, I. G., dos Santos, L. A. V., Rosa, D. V., Ribeiro, A. J. F., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.716686 · Cited by 24
Lombardi, G., Pancani, S., Manca, R., Mitolo, M., Baiardi, S., Massa, F., Coppola, L., Franzese, M., Nicolai, E., Guerini, F. R., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312916 · Cited by 23
Physiopathological mechanisms underlying Alzheimer’s disease: a narrative review
Engelhardt, E., Resende, E. D. P. F., & Gomes, K. B. (2024) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-vr01 · Cited by 23
Jiao, B., Ouyang, Z., Liu, Y., Zhang, C., Xu, T., Yang, Q., Zhang, S., Zhu, Y., Wan, M., Xiao, X., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01712-y · Cited by 23
Axelsson, T. G., Zetterberg, H., Blennow, K., Arslan, B., Ashton, N. J., Axelsson, M., Svensson, M. K. E., Saeed, A., & Guron, G. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04130-2 · Cited by 23
Self-citationFan, D., Jian, J.-M., Huang, S., Li, W., Shen, Y., Wang, Z., Zeng, G., Yi, X., Jin, W., Liu, Y.-H., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02016-7 · Cited by 23
Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease
Yu, X., Shao, K., Wan, K., Li, T., Li, Y., Zhu, X., & Han, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002566 · Cited by 23
Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic
Bucci, M., Blūma, M., Savitcheva, I., Ashton, N. J., Chiotis, K., Matton, A., Kivipelto, M., Molfetta, G. D., Blennow, K., Zetterberg, H., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02558-4 · Cited by 23
Self-citationAnkeny, S. E., Bacci, J. R., Decourt, B., Sabbagh, M. N., & Mielke, M. M. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00658-x · Cited by 23
Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease
Kac, P. R., Alcolea, D. A., Montoliu‐Gaya, L., Fernández, S., Lantero‐Rodriguez, J., Maure‐Blesa, L., González‐Ortiz, F., Benejam, B., Turton, M., Barroeta, I., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70172 · Cited by 23
Self-citationMiner, A. E., Groh, J. R., Tripodis, Y., Adler, C. H., Balcer, L. J., Bernick, C. B., Zetterberg, H., Blennow, K., Peskind, E. R., Ashton, N. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14231 · Cited by 22
Self-citationBiological functions of the m6A reader YTHDF2 and its role in central nervous system disorders
Song, L., Li, H., Yang, W., Yin, H., Wang, J., Guo, M., & Yang, Z. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116576 · Cited by 22
Blūma, M., Chiotis, K., Bucci, M., Savitcheva, I., Matton, A., Kivipelto, M., Jeromin, A., Santis, G. D., Molfetta, G. D., Ashton, N. J., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105504 · Cited by 22
Self-citationLongitudinal changes in the functional connectivity of individuals at risk of Alzheimer’s disease
García‐Colomo, A., Nebreda, A., Carrasco-Gómez, M., de Frutos‐Lucas, J., Ramírez‐Toraño, F., Spuch, C., Comís‐Tuche, M., Bruña, R., Alfonsín, S., & Maestú, F. (2024) · GeroScience · doi:10.1007/s11357-023-01036-5 · Cited by 22
Present and Future of Blood-Based Biomarkers of Alzheimer’s Disease: Beyond the Classics
Grigoli, M. M., Pelegrini, L. N. D. C., Whelan, R., & Cominetti, M. R. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148812 · Cited by 22
Recent advances in protein biomarkers based enzymatic biosensors for non-communicable diseases
Kaur, A., Rohilla, R., Rana, S., Rani, S., & Prabhakar, N. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117683 · Cited by 22
Do microbes play a role in Alzheimer's disease?
Williams, Z. A. P., Láng, L., Nicolas, S., Clarke, G. A., Cryan, J. F., Vauzour, D., & Nolan, Y. M. (2024) · Microbial Biotechnology · doi:10.1111/1751-7915.14462 · Cited by 22
Plasma p-tau181 and amyloid markers in Alzheimer’s disease: A comparison between Lumipulse and SIMOA
Quaresima, V., Pilotto, A., Trasciatti, C., Tolassi, C., Parigi, M., Bertoli, D., Mordenti, C., Galli, A., Rizzardi, A., Caratozzolo, S., et al. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.08.007 · Cited by 22
Self-citationAmyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
Ameen, T. B., Ali, U., Salma, O., Samee, M. A., Abbas, S. M. I., Kashif, S. N., Arifi, M. A., Ali, M., Khowaja, M., Ali, S. M. S., et al. (2025) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-025-00968-3 · Cited by 22
Fu, M., Wang, H., Bai, Q., Juanjuan, D., Niu, Q., & Nie, J. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.135911 · Cited by 22
Cerebral Amyloid Angiopathy and Downstream Alzheimer Disease Plasma Biomarkers
Kang, S. H., Lee, E. H., Kim, Y. J., Jang, H., Shin, D., Zetterberg, H., Blennow, K., González‐Ortiz, F., Ashton, N. J., Yun, J., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.8842 · Cited by 21
Self-citationEvaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials
Ferreira, P. C. L., Bellaver, B., Povala, G., Bauer‐Negrini, G., Aguzzoli, C. S., Ferrari‐Souza, J. P., Leffa, D. T., Soares, C., Lussier, F. Z., Medeiros, M. S., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000214441 · Cited by 22
Self-citationSerrano‐Pozo, A., Escott‐Price, V., Grinberg, L. T., Pascoal, T. A., Suárez‐Calvet, M., Dubois, B., & Sperling, R. A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00198-4 · Cited by 21
Self-citationGleerup, H. S., Sanna, F., Høgh, P., Simrén, J., Blennow, K., Zetterberg, H., Hasselbalch, S. G., Ashton, N. J., & Simonsen, A. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.659898 · Cited by 21
Self-citationTwo-Year Prognostic Utility of Plasma p217+tau across the Alzheimer's Continuum
Feizpour, A., Doré, V., Doecke, J. D., Saad, Z. S., Triana‐Baltzer, G., Slemmon, R., Maruff, P. T., Krishnadas, N., Bourgeat, P., Huang, K., et al. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.83 · Cited by 21
Is blood pTau a reliable indicator of the CSF status? A narrative review
Antonioni, A., Raho, E. M., & Lorenzo, F. D. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07258-x · Cited by 21
Niotis, K., Saperia, C., Saif, N., Carlton, C., & Isaacson, R. (2024) · Nature Mental Health · doi:10.1038/s44220-023-00191-0 · Cited by 21
Kim, S., Ma, X., Jeon, M. J., Song, S., Lee, J. S., Lee, J. U., Lee, C., Choi, S. H., & Sim, S. J. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116085 · Cited by 21
González‐Ortiz, F., Kirsebom, B., Yakoub, Y., Gundersen, J. K., Pålhaugen, L., Waterloo, K. K., Selnes, P., Jarholm, J. A., Gísladóttir, B., Rongve, A., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213676 · Cited by 21
Self-citationLocalization, induction, and cellular effects of tau phosphorylated at threonine 2171
Rajbanshi, B., Guruacharya, A., Mandell, J. W., & Bloom, G. S. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12892 · Cited by 20
Montoliu‐Gaya, L., Bian, S., Dammer, E. B., Alcolea, D. A., Sauer, M., Martá-Ariza, M., Ashton, N. J., Belbin, O., Fuchs, J., Watson, C. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61054-z · Cited by 20
Self-citationAlzheimer’s disease basics: we all should know
Das, S. K. (2025) · Neurological Research · doi:10.1080/01616412.2025.2529560 · Cited by 21
Wang, R., Lu, K. P., & Zhou, X. Z. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15909 · Cited by 20
Symptoms and conventional treatments of Alzheimer's disease
Chorawala, M. R., Shah, A. C., Pandya, A. J., Kothari, N. R., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00009-1 · Cited by 21
Engels, N., Riphagen, J. M., Egroo, M. V., Koops, E. A., Smegal, L. F., Becker, J. A., Prokopiou, P. C., Bueichekú, E., Kwong, K. K., Rentz, D. M., et al. (2024) · Annals of Neurology · doi:10.1002/ana.27022 · Cited by 20
Martínez‐Dubarbie, F., Guerra-Ruiz, A. R., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Infante, J., Pozueta‐Cantudo, A., García‐Martínez, M., Corrales‐Pardo, A., Bravo, M., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.152 · Cited by 20
Kwon, H. S., Hwang, M., Koh, S., Choi, S. H., Lee, J., Kim, H., Park, S., Park, H., Jeong, J. H., Han, M. H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-90232-8 · Cited by 20
Tau: a biomarker of Huntington’s disease
Lepinay, E., & Cicchetti, F. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02230-9 · Cited by 19
Day‐to‐day sleep variability with Alzheimer's biomarkers in at‐risk elderly
Baril, A., Picard, C., Labonté, A., Sanchez, E., Duclos, C., Mohammediyan, B., Ashton, N. J., Zetterberg, H., Blennow, K., Breitner, J. C. S., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12521 · Cited by 19
Self-citationPark, M., Ahn, J., Kim, Y.-J., Lee, J., Lee, J.-C., Hwang, S., & Kim, K. (2024) · Cells · doi:10.3390/cells13131085 · Cited by 19
Dayarathna, T. K., Roseborough, A. D., Gomes, J., Khazaee, R., Silveira, C. R. A., Borron, K., Yu, S., Coleman, K. K. L., Jesso, S., Finger, E. C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14087 · Cited by 19
Joynes, C. M., Bilgel, M., An, Y., Moghekar, A., Ashton, N. J., Kac, P. R., Karikari, T. K., Blennow, K., Zetterberg, H., Thambisetty, M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14405 · Cited by 19
Self-citationScarth, M., Rissanen, I. L., Scholten, R. J. P. M., & Geerlings, M. I. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210218 · Cited by 19
Taneva, S. G., Todinova, S. J., & Andreeva, T. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814296 · Cited by 18
Koike, R., Soeda, Y., Kasai, A., Fujioka, Y., Ishigaki, S., Yamanaka, A., Takaichi, Y., CHAMBERS, J. K., Uchida, K., Watanabe, H., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad359 · Cited by 18
Wang, X., Zhang, X., Liu, J., Zhang, J., Liu, C., Cui, Y., Song, Q., Hou, Y., Wang, Y., Zhang, Q., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01440-9 · Cited by 18
Chen, Y., Zeng, X., Diaz, J. L., Sehrawat, A., Lafferty, T. K., Boslett, J. J., Klunk, W. E., Pascoal, T. A., Villemagne, V. L., Cohen, A. D., et al. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16130 · Cited by 18
Self-citationPlasma phosphorylated-tau217 is increased in Niemann–Pick disease type C
González‐Ortiz, F., Karikari, T. K., Vruchte, D. T., Shepherd, D., Kirsebom, B., Fladby, T., Platt, F. M., & Blennow, K. (2024) · Brain Communications · doi:10.1093/braincomms/fcae375 · Cited by 18
Self-citationIdentify biological Alzheimer’s disease using a novel nucleic acid–linked protein immunoassay
Wang, Y., Ashton, N. J., Therriault, J., Benedet, A. L., Macedo, A. C., Pola, I., Aumont, É., Molfetta, G. D., Arias, J. F., Tan, K., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcaf004 · Cited by 18
Self-citationHigher plasma soluble TREM2 correlates with reduced cerebral tau accumulation in Alzheimer’s disease
Lan, G., Li, A., González‐Ortiz, F., Lv, J., Ran, W., Cai, Y. Q., Sun, P., Liu, L., Yang, J., Zhang, L., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02976-4 · Cited by 18
Self-citationZhang, Y., Ghose, U., Buckley, N. J., Engelborghs, S., Sleegers, K., Frisoni, G. B., Wallin, A., Lleó, A., Popp, J., Martínez‐Lage, P., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1040001 · Cited by 18
Self-citation
Metadata
- Authors
- Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., Gauthier, S., Vanmechelen, E., Zetterberg, H., Rosa-Neto, P., & Blennow, K.
- Affiliations
- King's College London (GB)
- University of Pittsburgh (US)
- University of Gothenburg (SE)
- McGill University (CA)
- National Hospital for Neurology and Neurosurgery (GB)
- McGill University Research Centre for Studies in Aging (CA)
- ADx NeuroSciences (BE)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Ashton, Nicholas J.
- Blennow, Kaj
- ORCID
- Venue
- Acta Neuropathologica
- Published
- 2021-02-14
- Volume
- 141
- Issue
- 5
- Pages
- 709-724
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC8043944
- OpenAlex
- W3131174931
- Cited by
- 719
- References
- 66
- Citations by year
- 2026: 122 · 2025: 165 · 2024: 148 · 2023: 112 · 2022: 126 · 2021: 46
- FWCI
- 77.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- University of Gothenburg
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau phosphorylation, blood biomarkers, Simoa, amyloid PET, Braak staging, cognitive impairment, mild cognitive impairment, cerebrospinal fluid biomarkers, neurodegeneration, early detection of Alzheimer's disease, [18F]MK-6240
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Phosphorylation, Biomarkers, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.